IP Library Granted Patent US 10,948,495
Granted Patent B2
US 10,948,495 · App. 15/974,921 · Granted Mar 16, 2021

Methods and reagents for analyzing protein-protein interfaces

Inventors: Gregory L. Verdine (Boston, MA); M. James Nichols (Charlestown, MA); Sharon A. Townson (Cambridge, MA); Uddhav Kumar Shigdel (Cambridge, MA); Seung-Joo Lee (Cambridge, MA); Dylan T. Stiles (Chestnut Hill, MA); Neville J. Anthony (Northborough, MA)
Assignee: Revolution Medicines, Inc.
G01N33/6845C07K1/086C07K1/13C07K5/0215C07K5/06034C07K5/0808C07K7/64C07K7/645C12Q1/533G01N33/566G01N2333/82G01N2333/90209G01N2410/08G01N2500/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,948,495
App. No.
15/974,921
Granted
Mar 16, 2021
Kind
B2
Abstract

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

Claims (15)

1. A compound, or salt thereof, which binds to cyclophilin and which has the structure:

A-L-B,

wherein A is a cyclophilin binding moiety having the structure of Formula III:

wherein Z 3 and Z 4 are each, independently, hydroxyl, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, or Z 3 and Z 4 combine to form, with the atoms to which they are attached, an optionally substituted 13 to 40 member macrocycle;

Z 4 comprises a point of attachment to L;

R 5 is optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 2 -C 6 heteroalkenyl, optionally substituted C 2 -C 6 heteroalkynyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 6 -C 10 optionally substituted C 6 -C 10 aryl C 1 -C 6 alkyl, optionally substituted C 2 -C 9 heterocyclyl, or optionally substituted C 2 -C 9 heterocyclyl C 1 -C 6 alkyl;

R 6 is optionally substituted C 1 -C 6 alkyl;

L is a linker having the structure:

A 1 -(B 1 ) f —(C 1 ) g —(B 2 ) h -(D)-(B 3 ) i —(C 2 ) j —(B 4 ) k -A 2

wherein A 1 is a bond between the linker and A; A 2 is a bond between B and the linker; B 1 , B 2 , B 3 , and B 4 each, independently, is selected from optionally substituted C 1 -C 2 alkyl, optionally substituted C 1 -C 3 heteroalkyl, O, S, and NR N ; R N is hydrogen, optionally substituted C 1-4 alkyl, optionally substituted C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, optionally substituted C 2-6 heterocyclyl, optionally substituted C 6-12 aryl, or optionally substituted C 1-7 heteroalkyl; C 1 and C 2 are each, independently, selected from carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; f, g, h, l, j, and k are each, independently, 0 or 1; and D is optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted C 2-6 heterocyclyl, optionally substituted C 6-12 aryl, optionally substituted C 2 -C 10 polyethylene glycol, or optionally substituted C 1-10 heteroalkyl, or a chemical bond linking A 1 -(B 1 ) f —(C 1 ) g —(B 2 ) h — to —(B 3 ) i —(C 2 ) j —(B 4 ) k -A 2 ; and

B is a cross-linking group, wherein the cross-linking group is a maleimide, vinyl sulfone having the structure

isocyanate, isothiocyanate, or haloheteroaryl.

2. The compound, or salt thereof, of claim 1 , wherein the cross-linking group is a maleimide.

3. The compound, or salt thereof, of claim 1 , wherein the interaction between the cyclophilin binding moiety and cyclophilin is non-covalent.

4. The compound, or salt thereof, of claim 1 , wherein the cyclophilin binding moiety is a cyclophilin binding moiety capable of binding PP1A, CYPB, CYPC, CYP40, CYPE, CYPD, NKTR, SRCyp, CYPH, CWC27, CYPL1, CYP60, CYPJ, PPIL4, PPIL6, RANBP2, or PPWD1.

Assignments (3)
SECURITY INTEREST Recorded Jun 25, 2025
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 071721/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2019
From: WARP DRIVE BIO, INC.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 050473/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2018
From: VERDINE, GREGORY L.; NICHOLS, M. JAMES; TOWNSON, SHARON A.; SHIGDEL, UDDHAV KUMAR; LEE, SEUNG-JOO; STILES, DYLAN T.; ANTHONY, NEVILLE J.
To: WARP DRIVE BIO, INC.
Reel/Frame 045871/0216 →